Alzheimer's disease (AD) affects millions of people and is a major rising problem in health care worldwide. Recent research suggests that AD could have different subtypes, presenting differences in how the disease develops. Characterizing those subtypes could be key to deepen the understanding of this complex disease. In this paper, we used a multivariate, non-supervised clustering method over blood-based markers to find subgroups of patients defined by distinctive blood marker profiles. Our analysis on ADNI database identified 4 possible subgroups, each with a different blood profile. January 4, 2019 1/26
Introduction
We preselected 235 candidate plasma markers from the available cohort of cortical thickness of the whole brain for interaction analysis. The full list of the selected 80 plasma markers and brain regions can be found in supplementary files S2 and S3. 81 Each volume value was normalized by the estimated intracraneal volume of the 82 subject. Both structural volumes and plasma markers were standardized to [0, 1] range 83 before processing, We used min-max scaling, substracting the minimum value of each 84 biomarker and dividing by the difference between the maximum and the minimum. 85 This way, we preserve zero entries and introduce robustness to small standard 86 deviations in the biomarkers. 87 
Methods

88
To find the different profiles, we cluster the patients using their blood markers, without 89 using neither brain phenotypes nor diagnosis. We analyze the resulting clusters to find 90 the blood profiles of each cluster. To find heterogeneous brain presentations in each 91 cluster, we analyze the relationships between brain phenotypes in each cluster and 92 disease stage, thus revealing the interactions between blood marker profiles and brain 93 phenotypes across the disease stages. Fig 1 shows the pipeline of the method. 94 Unsupervised clustering 95 We use CIMLR (which originally stands for cancer integration via multikernel learning, 96 since it was developed for cancer subtyping) [19, 23] , to identify the blood markers that 97 reveal natural subgroups in the data, without taking into account neither the brain 98 phenotypes nor the disease stage, to obtain subtypes not defined by disease stage. We 99 could have used any other unsupervised clustering method, but we selected CIMLR, 100 coupled with manifold learning and k-means clustering, due to its scalability with large 101 amounts of data, good performance on a variety of datasets [19, 23] , and interpretability 102 of results.
103
CIMLR is a method based on multiple kernel learning that learns a similarity 104 between each pair of samples by combining different kernels per feature (in our case, 105 blood markers). It enforces a C block structure on the learned similarity, where each 106 block is a set of samples similar to each other, i.e., a cluster. The number of clusters C 107 must be specified beforehand. The learned similarity can then be used to compute a clusters in S). The optimization problem is defined as follows:
Here, γ, µ, and β are tuning parameters for the various terms of the optimization can be found in [19] . A MATLAB implementation of the method by the authors of the 129 paper has been used (https://github.com/BatzoglouLabSU/SIMLR). 130 We use Gaussian kernels to define K mp . In total, there are P kernels for each 131 feature m, each with different parameters. This is needed because different markers 132 could be sensitive to different ranges of parameters. We define K mp as: in [24] , and further validate the choice with the elbow method. For visualization of the 140 clusters and dimensionality reduction, we apply t-distributed stochastic neighbor 141 embedding (t-SNE) [25] , a manifold learning technique, on the resulting similarity 142 matrix. After obtaining the low dimensional embedding, k-means clustering is used to 143 discover the clusters.
144
Cluster validation 145 We want to test the stability of the clusters against perturbations (e.g. particular choice 146 of individuals). If the same clusters arise after modifying the choice of individuals, this 147
suggests that the clustering is capturing an underlying structure in the data that is 148 invariant to the particular choice of individuals, to some extent. We use a bootstrap 149 procedure to test this stability. We apply the CIMLR-based clustering method to 150 randomly select subsets of the data, with the same size of the original dataset but with 151 replacement (i.e. some patients could appear several times, wheras others could not 152 appear at all). After applying the clustering algorithm, we compute the similarity of the 153 obtained clusters in each bootstrap iteration with the clusters obtained for the whole 154 dataset. 155 We use the Jaccard index to quantify the similarity between clusters. This Jaccard 156 index is defined, for two sets A, B, as the intersection divided by the union of the sets: 157
The higher the index, the higher the similarity and hence the stability.
158
Profile discovery 159 Subjects in a given cluster share a specific profile of blood markers. To obtain the 160 profile of each cluster, we need to determine which markers contributed more to the 161 clustering. We look at the weights w in the optimization procedure: each weight 162 accounts for the importance of a specific kernel. As described above, we generate 15 163 kernels for each of the 172 markers, with 15 associated weights. We compute the 164 importance as the sum of those weights.
For further validation, we use one-way analysis of variance (ANOVA) tests of mean 166 population across the clusters for the described markers to test whether the population 167 of each subtype has a different mean. With this, we obtain a stable list of the most 168 informative markers for the clustering, and describe the different blood profiles in each 169 subgroup according to that set of markers.
170
Interaction analysis 171
To detect different interactions between blood markers and structural brain phenotypes, 172
we test for differences between the brain volumes and cortical thickness of the 173 individuals in each subgroup. We perform three different comparison tests: the rest of subjects on the population in that diagnostic group, to detect different 182
interactions between blood profiles and structural brain phenotypes across 183 different stages of the disease. 184 We want to know whether cluster membership (independent variable) has significant 185 effects on brain volume/cortical thickness (dependent variable to ensure that the obtained statistical significance was not caused by the different 197 sample sizes of each subgroup and each diagnostic group. Fig 2 shows an outline of the 198 procedure.
199
We use a non-parametric Mann-Whitney-Wilcoxon test for comparing the brain 200 subvolumes. For cortical thickness, we use FreeSurfer's mri glmfit-sim and fsPalm to 201 implement the analysis. We also perform a cluster-wise correction on the surface of the 202 cortex and applied Bonferroni correction for the two hemispheres. In this way, we can 203 map corrected regions in the cortex that present significant differences in each analysis. 204 We applied the proposed method to the described cohort of subjects from ADNI After applying the heuristics on cluster size described in the Methods section, we 212 obtained C ∈ {4, 6} using [24] and C ∈ {4, 5} using the elbow method. We decided on 213 C = 4 as the most appropriate choice. Figure 3 shows the learned similarity matrix S whereas CIMLR has a block structure that improves dimensionality reduction and 219 cluster analysis. 220 We assessed the stability of the obtained clusters by using the bootstrap approach 221 described in the Methods section and compared it with stability results obtained using a 222 random clustering and k-means clustering with Euclidean metric. Table 2 shows the 223 results. CIMLR got a larger mean similarity in each cluster than random clustering, 224 and similar stability to k-means clustering. Clusters C1 and C2 appeared more stable 225 than C3 and C4. Examination results and APoE4 genotype) are also similar across subgroups, with the 230 exception of the mean age of C4, which is 5 years lower than the mean population, and 231 a slightly higher fraction of women in C3 and C4. No major significant differences 232 between subgroups were observed, meaning that the obtained groups were not biased.
226
233
Blood marker ranking and profiling 234 CIMLR revealed patterns of plasma markers that relate to natural subgroups. Fig 4   235 shows the ten most relevant markers determined by the weight vector w. The method 236 uses all blood markers to find the clusters but, unlike other methods, it automatically 237 weights each marker. S4 data contains the full set of weights.
238 Fig 5 shows the values for each marker and cluster. All the ANOVA tests done for markers that were highly correlated to the disease stage (such as the tau and amyloid 255 related markers) had been selected by the algorithm, then that distribution would have 256 been biased.
257
Interaction analysis 258 We analyzed the heterogeneity between the different groups and the interactions 259 between the stages of the disease and the brain volume and cortical thickness 260 phenotypes depending on the blood profiles in each subgroup, as described in the 261 Methods section.
262
Whole cluster analysis 263 We compared subcortical brain volumes in each subgroup against the rest of the 264 population, corrected for different group sizes and false positives using permutation tests. 265 anterior, whereas C3 is only different to the rest in the right accumbens area. C4 shows 270 many differences in the choroid plexus, ventricles, putamen and pallidum, among others. 271 We also tested for cortical thickness differences. cortex. We did not detect any differences in C2 and C3, which is consistent with the 275 previous results on subcortical volume analysis. 
Diagnostic group analysis 277
To identify differences between diagnostic groups in each of the subgroups, we compared 278 between diagnostic groups (CN, MCI, AD) for each of the different subgroups (C1 to 279 C4). In this task, permutation tests allow us to detect differences between diagnostic 280 groups that are specific to that subgroup, by correcting the result against random 281 subgroups. Figs 8 and 9 show the difference between diagnostic groups in: (i) each of the subgroups (Fig 8) and (ii) the whole population (Fig 9) .
283
There are significant differences in C3 between CN and AD subjects in the corpus 284 callosum, the third ventricle and the choroid plexus, and in C4 between CN and MCI 285 subjects in the corpus callosum and the ventricles. C1 and C2 have more sparse 286 differences with respect to the whole population. Most of the statistically significant 287 differences correspond to volumes that show less significant differences on the whole 288 population analysis. Intra-group heterogeneity between disease stages is located in 289 specific regions that are usually less affected by the disease. 290 We only detected differences in cortical thickness when testing on CN vs MCI in C4, 291
after correcting for multiple comparisons. Fig 10 shows the detected regions on the 292 cortical surface, located on the frontal cortex and on the right temporal and parietal 293 regions.
294
Diagnostic interaction analysis 295
To detect different interactions between blood profiles and brain phenotypes across 296 different stages of the disease, we tested for differences across same diagnostic subgroups 297
for each cluster against the rest of the population with the same diagnosis. Fig 11 shows zones of the cingular cortex. MCI presents differences in the ventricles, left and 311 right choroid plexus and left accumbens area, among others. AD also shows some 312 differences esspecially in the left pallidum.
313
In cortical analysis, we found significant differences in MCI and AD patients of C4 314 -which also presented many differences in our subvolume analysis-in the central and 315 frontal regions of both hemispheres (see Fig 12) .
316
Discussion
317
We applied a multivariate data-driven procedure for AD subtyping using blood-based 318 markers, to obtain heterogeneous groups with different blood marker profiles. We 319 showed that patients with different profiles present different interactions between 320 disease stage and brain phenotypes. Although existing blood markers can still not be 321 used to properly diagnose the disease [7, 29, 30] , using blood markers to detect patient 322 profiles where the disease could behave differently and could provide valuable biological 323 insights is a promising research direction.
324
The method identifies natural subgroups of patients in a multivariate way, finding 325 hidden associations between the markers and automatically weighting the most 326 important ones. The method is scalable to a large number of subjects and to a large genotypes or other not-included blood markers. It also has some limitations: the 329 obtained subgroups do not have a high stability. We also did not compare to other 330 possible subtyping methods to further validate the obtained results. heterogeneous disease. Further validation of the results on a larger, independent cohorts 335 of patients will be important to confirm the results and detect more complex profiles.
336
Interactions of the profiles could also be further validated in other phenotypes, such as 337 longitudinal brain atrophy.
338
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